Join the 'Vasculitis' group to help and get support from people like you.
Posted 27 Nov 2011 by Drugs.com
FRIDAY, Nov. 25 – Patients hospitalized for autoimmune disorders, like rheumatoid arthritis or Crohn's disease, may be at greater risk for a life-threatening pulmonary embolism, a clot in a main artery of the lung, a new study finds. Reporting online Nov. 25 in The Lancet, researchers warned that steps should be taken to prevent this condition among patients admitted to the hospital for autoimmune diseases. In conducting the study, researchers analyzed data on more than 500,000 patients admitted to the hospital in Sweden for one of 33 autoimmune diseases, which can also include Grave's disease, Hashimoto's thyroiditis and chronic rheumatic heart disease. The team, led by Dr. Bengt Zoller of Malmo University Hospital in Sweden, found the overall risk of pulmonary embolism in the 12 months following hospitalization to be six times higher for patients with autoimmune diseases than for ... Read more
Related support groups: Rheumatoid Arthritis, Crohn's Disease, Hashimoto's Disease, Pulmonary Embolism, Vasculitis, Graves' Disease, Polymyositis/Dermatomyositis, Chronic Lymphocytic Thyroiditis, Rheumatic Heart Disease, Polyarteritis
Posted 8 Nov 2010 by Drugs.com
MONDAY, Nov. 8 – New research suggests that a newer drug works no better than an older, cheaper medication for patients who need long-term treatment for a type of vasculitis, a rare blood vessel disorder. The older drug, azathioprine, "beat out the new kid on the block," said Dr. Ronald Falk, a kidney specialist familiar with the findings. But that's not necessarily good news because relapses and serious side effects are common over time. Vasculitis strikes about one in every 100,000 people, Falk said. An overly aggressive response by the immune system causes the blood vessels of the body to swell, creating problems in the kidneys and lungs. Azathioprine (Azasan) is currently used for long-term treatment of patients with a form of the disease known as antineutrophil cytoplasmic antibody-associated vasculitis. The new study compares the drug to another medication, mycophenolate mofetil ... Read more
Posted 14 Jul 2010 by Drugs.com
WEDNESDAY, July 14 – A drug already used to treat lymphoma and rheumatoid arthritis shows promise as an option to treat rare forms of vasculitis, a disease affecting the blood vessels, according to two new studies. The drug, rituximab, appeared to be as effective as the current standard, cyclophosphamide, in treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Rituximab may even be superior to cyclophosphamide in treating disease recurrences, the researchers found. This is the first time in 40 years that a new drug has emerged to treat these conditions, according to the authors of the studies, both appearing in the July 15 issue of the New England Journal of Medicine. "This trial has demonstrated for the first time there is an effective alternative to cyclophosphamide for remission induction, and there are a variety of results that make us think that rituximab ... Read more